NCT00289341View on ClinicalTrials.gov

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

vaccine vehicle only

Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.

BIOLOGICAL

DC/LNCaP

Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH

Trial Locations (1)

10021

Rockefeller University Hospital, New York

All Listed Sponsors
lead

Rockefeller University

OTHER

NCT00289341 - Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells. | Biotech Hunter | Biotech Hunter